Tag Archives: Kisqali demonstrates sustained outcomes across trials as Novartis highlights long-term control and recurrence reduction

Novartis reports four-year progression-free durability for one in four Kisqali-treated metastatic breast cancer patients

Posted on 9, December 2025 by EuropaWire PR Editors

(IN BRIEF) Novartis announced new MONALEESA pooled analysis results showing that 25% of HR+/HER2- metastatic breast cancer patients treated first-line with Kisqali plus endocrine therapy remained progression-free for four or more years, with a median PFS of 6.8 years. Durable … Read the full press release →

Posted in Business, Healthcare, Pharma & Biotech, Switzerland

Tagged biomarkers, CDK4/6 inhibitor, ctDNA, early breast cancer, endocrine partner therapy, endocrine therapy, ESMO MCBS rating, global oncology research, HR+/HER2- breast cancer, Kisqali demonstrates sustained outcomes across trials as Novartis highlights long-term control and recurrence reduction, Kisqali®, long-term progression-free survival, Luminal A subtype, Mark Rutstein, metastatic breast cancer, MONALEESA trials, NATALEE trial, NCCN Category 1, Novartis, OS benefit, Pedram Razavi, precision oncology, ribociclib, SAN ANTONIO Breast Cancer Symposium SABCS